Understanding Fas/CD95 in Triple Negative Breast Cancer
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
This project explores how a protein called Fas/CD95 helps triple negative breast cancer grow by weakening the body's immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11097328 on NIH RePORTER |
What this research studies
Triple negative breast cancer (TNBC) is a challenging type of breast cancer because it currently lacks specific treatments. We know that a protein called Fas/CD95 plays a role in how cells grow and die, but in TNBC, it seems to help the cancer survive. This project aims to understand how Fas/CD95 might suppress the immune system, allowing cancer cells to escape detection and grow. By uncovering these mechanisms, we hope to find new ways to target TNBC.
Who could benefit from this research
Good fit: This foundational research focuses on understanding the biology of triple negative breast cancer, and while not directly recruiting patients, it is relevant to those living with this condition.
Not a fit: Patients with other types of breast cancer or different conditions may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to the development of new targeted therapies for triple negative breast cancer patients by disrupting the cancer's ability to suppress the immune system.
How similar studies have performed: This project builds on new preliminary data and recent discoveries, suggesting a novel approach to understanding Fas/CD95's role in immune suppression in TNBC.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Peter, Marcus E. — Northwestern University
- Study coordinator: Peter, Marcus E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.